Ridgecrest Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.06M Buy
884
+24
+3% +$24.5K 0.51% 38
2026
Q1
$791K Sell
860
-20
-2% -$20.3K 0.44% 48
2025
Q4
$946K Sell
880
-7
-0.8% -$6.69K 0.51% 40
2025
Q3
$677K Buy
887
+3
+0.3% +$2.23K 0.31% 57
2025
Q2
$689K Sell
884
-27
-3% -$21K 0.36% 51
2025
Q1
$752K Hold
911
0.39% 49
2024
Q4
$703K Buy
911
+95
+12% +$78.7K 0.38% 50
2024
Q3
$723K Sell
816
-40
-5% -$36K 0.38% 49
2024
Q2
$775K Hold
856
0.47% 42
2024
Q1
$666K Hold
856
0.4% 52
2023
Q4
$499K Buy
856
+10
+1% +$5.84K 0.33% 57
2023
Q3
$454K Hold
846
0.32% 56
2023
Q2
$397K Sell
846
-4
-0.5% -$1.68K 0.26% 62
2023
Q1
$292K Hold
850
0.21% 74
2022
Q4
$311K Sell
850
-200
-19% -$70.9K 0.24% 67
2022
Q3
$340K Sell
1,050
-100
-9% -$31.7K 0.28% 65
2022
Q2
$373K Hold
1,150
0.27% 63
2022
Q1
$329K Sell
1,150
-370
-24% -$95.2K 0.21% 84
2021
Q4
$420K Hold
1,520
0.2% 84
2021
Q3
$351K Buy
+1,520
New +$375K 0.19% 85

Other funds holding LLY

Ridgecrest Wealth Partners's LLY Position: Q2 2026 in Review

Ridgecrest Wealth Partners increased its Eli Lilly (LLY) stake by 2.8% in Q2 2026, buying an estimated $24.5K and bringing the position to 884 shares worth $1.06M. The position accounts for 0.51% of the portfolio, ranked #38.

Ridgecrest Wealth Partners first reported a position in LLY in Q3 2021 and has held it in 20 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Ridgecrest Wealth Partners held 884 shares of Eli Lilly worth $1.06M as of Q2 2026.
  • Ridgecrest Wealth Partners bought 24 Eli Lilly shares in Q2 2026, an estimated $24.5K.
  • Eli Lilly made up 0.51% of Ridgecrest Wealth Partners's portfolio in Q2 2026, its #38 holding.
  • Ridgecrest Wealth Partners first reported a position in Eli Lilly in Q3 2021 and has held it in 20 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Ridgecrest Wealth Partners's 13F filing for Q2 2026, filed 5 Aug 2026.